U.S. Radiopharmaceutical Therapies Market Size, Share, and Trends 2025 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on U.S. Radiopharmaceutical Therapies Market 

5.1. COVID-19 Landscape: U.S. Radiopharmaceutical Therapies Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. U.S. Radiopharmaceutical Therapies Market, By Therapy Type

8.1. U.S. Radiopharmaceutical Therapies Market Revenue and Volume, by Therapy Type

8.1.1. Targeted Alpha Therapy (TAT)

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Targeted Beta Therapy

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Brachytherapy-based Radiopharmaceuticals

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Auger Electron Emitting Radiopharmaceuticals (emerging)

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Others

8.1.5.1. Market Revenue and Volume Forecast

Chapter 9. U.S. Radiopharmaceutical Therapies Market, By Radioisotope Used

9.1. U.S. Radiopharmaceutical Therapies Market Revenue and Volume, by Radioisotope Used

9.1.1. Beta Emitters

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Alpha Emitters

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Brachytherapy-based Radiopharmaceuticals

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Auger Electron Emitting Radiopharmaceuticals (emerging)

9.1.4.1. Market Revenue and Volume Forecast

9.1.5. Others

9.1.5.1. Market Revenue and Volume Forecast

Chapter 10. U.S. Radiopharmaceutical Therapies Market, By Therapeutic Area 

10.1. U.S. Radiopharmaceutical Therapies Market Revenue and Volume, by Therapeutic Area

10.1.1. Oncology

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Non-Oncology

10.1.2.1. Market Revenue and Volume Forecast

Chapter 11. U.S. Radiopharmaceutical Therapies Market, By Route of Administration

11.1. U.S. Radiopharmaceutical Therapies Market Revenue and Volume, by Route of Administration

11.1.1. Intravenous Injection

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Oral (primarily Iodine-131)

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Intra-arterial

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Intratumoral (investigational)

11.1.5.1. Market Revenue and Volume Forecast

Chapter 12. U.S. Radiopharmaceutical Therapies Market, By End-User

12.1. U.S. Radiopharmaceutical Therapies Market Revenue and Volume, by End-User

12.1.1. Hospitals

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Radiopharmacies

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Ambulatory Surgical Centers (ASCs)

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Nuclear Medicine Centers

12.1.4.1. Market Revenue and Volume Forecast

Chapter 13. U.S. Radiopharmaceutical Therapies Market, Estimates and Trend Forecast

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Therapy Type

13.1.6.2. Market Revenue and Volume Forecast, by Radioisotope Used

13.1.6.3. Market Revenue and Volume Forecast, by Therapeutic Area

13.1.6.4. Market Revenue and Volume Forecast, by Route of Administration

13.1.6.5. Market Revenue and Volume Forecast, by End-User 

Chapter 14. Company Profiles

14.1. Bayer

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Novartis

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Novartis

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Q BioMed

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. China Isotope & Radiation

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Curium Pharmaceuticals

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Abbott

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Jubilant DraxImage

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Lantheus

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Spectrum Pharmaceuticals

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms